Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Administration of Tumor-Associated Antigen (TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL)

X
Trial Profile

Administration of Tumor-Associated Antigen (TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zedenoleucel (Primary)
  • Indications Hodgkin's disease; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Acronyms pediTACTAL
  • Most Recent Events

    • 11 Mar 2024 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Jan 2024 to 1 Apr 2024.
    • 14 Jul 2022 Planned initiation date changed from 4 Apr 2022 to 4 Sep 2022.
    • 14 Jul 2022 Planned initiation date (estimated date for recruitment of the first subject) changed from 4 Apr 2022 to 4 Sep 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top